Literature DB >> 31814296

Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Ming-Yii Huang1,2,3,4,5, Ching-Wen Huang6,7, Jaw-Yuan Wang3,4,5,6,7,8,9.   

Abstract

Colorectal cancer is a major public health problem worldwide, and locally advanced rectal cancer (LARC) is known for its poor prognosis. A multimodal treatment approach is the only method to achieve satisfactory local recurrence and survival rates in LARC. Determining which therapeutic modality for LARC has the most satisfactory influence on quality of life and disease outcome is still controversial. LARC treatment is subject to continuous advancement due to the development of new and better diagnostic tools, radiotherapy techniques, and chemotherapeutic agents. Herein, we review various therapeutic modalities for LARC from several aspects. In addition to radiotherapy techniques such as neoadjuvant chemoradiotherapy (NCRT), we discuss the progress of chemotherapy, appropriate time interval between NCRT and surgery, relationship between tumor location and NCRT efficacy/safety, wait-and-watch policy, and predictors of treatment response following NCRT. Because of the controversies and unanswered questions regarding NCRT treatments for LARC, additional investigations are required to determine which therapeutic approach is the most feasible for LARC patients.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  local recurrence; locally advanced rectal cancer; neoadjuvant chemoradiotherapy; surgery

Mesh:

Year:  2019        PMID: 31814296     DOI: 10.1002/kjm2.12161

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  7 in total

1.  BMI May Be a Prognostic Factor for Local Advanced Rectal Cancer Patients Treated with Long-Term Neoadjuvant Chemoradiotherapy.

Authors:  Hengchang Liu; Ran Wei; Chunxiang Li; Zhixun Zhao; Xu Guan; Ming Yang; Zheng Liu; Xishan Wang; Zheng Jiang
Journal:  Cancer Manag Res       Date:  2020-10-20       Impact factor: 3.989

2.  An observational study of patho-oncological outcomes of various surgical methods in total mesorectal excision for rectal cancer: a single center analysis.

Authors:  Yi-Ting Chen; Ching-Wen Huang; Cheng-Jen Ma; Hsiang-Lin Tsai; Yung-Sung Yeh; Wei-Chih Su; Chee-Yin Chai; Jaw-Yuan Wang
Journal:  BMC Surg       Date:  2020-02-03       Impact factor: 2.102

3.  Time interval between the completion of radiotherapy and robotic-assisted surgery among patients with stage I-III rectal cancer undergoing preoperative chemoradiotherapy.

Authors:  Ching-Wen Huang; Wei-Chih Su; Tzu-Chieh Yin; Po-Jung Chen; Tsung-Kun Chang; Yen-Cheng Chen; Ching-Chun Li; Yi-Chien Hsieh; Hsiang-Lin Tsai; Jaw-Yuan Wang
Journal:  PLoS One       Date:  2020-10-16       Impact factor: 3.240

4.  Evaluation of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio on Predicting Responsiveness to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients.

Authors:  Maoxi Liu; Yi Feng; Yixun Zhang; Haiyi Liu
Journal:  Biomed Res Int       Date:  2022-09-28       Impact factor: 3.246

5.  Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.

Authors:  Yi-Ting Chen; Tzu-Ting Tseng; Hung-Pei Tsai; Shih-Hsun Kuo; Ming-Yii Huang; Jaw-Yuan Wang; Chee-Yin Chai
Journal:  Hum Cell       Date:  2022-09-02       Impact factor: 4.374

6.  Metabolic reprogramming-associated genes predict overall survival for rectal cancer.

Authors:  Zhong-Yi Zhang; Qing-Zhi Yao; Hui-Yong Liu; Qiao-Nan Guo; Peng-Jun Qiu; Jian-Peng Chen; Jian-Qing Lin
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310

7.  Oncological Outcomes of Robotic-Assisted Surgery With High Dissection and Selective Ligation Technique for Sigmoid Colon and Rectal Cancer.

Authors:  Tzu-Chieh Yin; Wei-Chih Su; Po-Jung Chen; Tsung-Kun Chang; Yen-Cheng Chen; Ching-Chun Li; Yi-Chien Hsieh; Hsiang-Lin Tsai; Ching-Wen Huang; Jaw-Yuan Wang
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.